Latest The Medicines Company (MDCO) Headlines
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in The Medicines Company to Contact Brower Piven Before the April 22, 2014 Lead Plaintiff Deadline (MDCO)
GlobeNewswire - Wed Mar 12, 12:14PM CDT
Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of The Medicines Company ("Medicines" or the "Company") (Nasdaq:MDCO) securities during the period between February 20, 2013 and February 12, 2014, inclusive (the "Class Period").
THE MEDICINES COMPANY SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Class Action Against THE MEDICINES COMPANY and Its Board of Directors and a Lead Plaintiff Deadline of April 22, 2014 -- MDCO
PR Newswire - Tue Mar 11, 1:33PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased The Medicines Company ("Medicines" or the "Company") (NasdaqGS: MDCO) securities between February 20, 2013 and February 12, 2014.
17.3% Return Seen to Date on SmarTrend Medicines Co Call (MDCO)
Comtex SmarTrend(R) - Fri Mar 07, 5:05PM CST
SmarTrend identified a Downtrend for Medicines Co (NASDAQ:MDCO) on January 29th, 2014 at $36.13. In approximately 1 month, Medicines Co has returned 17.33% as of today's recent price of $29.87.
Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in The Medicines Company of Class Action Lawsuit and Upcoming Deadline -- MDCO
GlobeNewswire - Fri Mar 07, 4:54PM CST
Pomerantz LLP has filed a class action lawsuit against The Medicines Company ("Medicines" or the "Company") (Nasdaq:MDCO) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 2:33-av-00001, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Medicines securities between February 20, 2013 and February 12, 2014 both dates inclusive (the "Class Period"). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.
The Medicines Company to Participate in 2014 Barclays Global Healthcare Conference
Marketwire - Thu Mar 06, 10:20AM CST
The Medicines Company (NASDAQ: MDCO) is scheduled to present at the 2014 Barclays Global Healthcare Conference in Miami, FL on March 12th at 1:00 PM Eastern Time.
EQUITY ALERT: The Rosen Law Firm, P.A. Announces the Filing of a Class Action Lawsuit Against The Medicines Company -- MDCO
GlobeNewswire - Tue Mar 04, 11:32AM CST
The Rosen Law Firm, P.A. announces that a class action lawsuit has been filed on behalf of purchasers of the securities of The Medicines Company (Nasdaq:MDCO) between February 20, 2013 and February 12. 2014, inclusive (the "Class Period") seeking remedies under the federal securities laws.
INVESTOR ALERT: Class Action Lawsuit Against The Medicines Company Announced by Law Offices of Howard G. Smith
Business Wire - Tue Mar 04, 9:32AM CST
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all purchasers of the securities of The Medicines Company (NASDAQ:MDCO) between February 20, 2013 and February 12, 2014, inclusive (the "Class Period").
EU Review for The Medicines Co.'s Oritavancin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 4:55PM CST
The Medicines Co.'s marketing authorization application for oritavancin accepted by the European Medicines Agency (EMA) for review.
Attention The Medicines Company Investors: The Medicines Company Misled Investors According to a Recently Filed Class Action
PR Newswire - Mon Mar 03, 2:19PM CST
Shareholder rights law firm Robbins Arroyo LLP announces that an investor of The Medicines Company (NASDAQ: MDCO) has filed a federal securities fraud class action complaint in the U.S. District Court for the District of New Jersey. The complaint alleges that the company and certain of its officers and directors violated the Securities and Exchange Act of 1934 between February 20, 2013 and February 12, 2014 (the "Class Period"). Medicines is a global pharmaceutical company that specializes in providing medical solutions for critical care patients in acute intensive care hospitals worldwide.
Medicines Co Has Returned 13.1% Since SmarTrend Recommendation (MDCO)
Comtex SmarTrend(R) - Fri Feb 28, 11:20AM CST
SmarTrend identified a Downtrend for Medicines Co (NASDAQ:MDCO) on January 29th, 2014 at $36.13. In approximately 1 month, Medicines Co has returned 13.12% as of today's recent price of $31.39.
The Medicines Company's MAA for oritavancin for acute bacterial skin and skin structure infections accepted for review by EMA
M2 - Fri Feb 28, 5:49AM CST
Hospital company The Medicines Company (NASDAQ:MDCO) stated on Thursday that its marketing authorisation application (MAA) for the investigational intravenous antibiotic oritavancin for the treatment of complicated skin and skin tissue infections (cSSTI) has been accepted for review by the European Medicines Agency (EMA).
INVESTOR ALERT: Class Action Lawsuit Against The Medicines Company Announced by Glancy Binkow & Goldberg LLP
Business Wire - Thu Feb 27, 9:32AM CST
Glancy Binkow & Goldberg LLP announces that a class action lawsuit has been filed on behalf of all purchasers of the securities of The Medicines Company (NASDAQ:MDCO) between February 20, 2013 and February 12, 2014, inclusive (the "Class Period"). If you purchased The Medicines Company shares during the Class Period, please contact us toll-free at (888) 773-9224, or at (212) 682-5340, or by email to shareholders@glancylaw.com to discuss this matter.
European Medicines Agency Accepts Marketing Authorization Application for The Medicines Company's Oritavancin
Marketwire Canada - Thu Feb 27, 7:45AM CST
The Medicines Company (NASDAQ: MDCO) today announced that the European Medicines Agency (EMA) has accepted for review a marketing authorization application (MAA) for the investigational intravenous antibiotic, oritavancin, for the treatment of complicated skin and skin tissue infections (cSSTI), caused by susceptible gram-positive bacteria, including by methicillin-resistant Staphylococcus aureus (MRSA), administered as a single dose.
Lifshitz & Miller Law Firm Announces Investigation of Emeritus Corporation, Nu Skin Enterprises, Inc., The Medicines Company, Thoratec Corporation and TriQuint Semiconductor, Inc.
PR Newswire - Wed Feb 26, 9:50AM CST
Emeritus Corporation
THE MEDICINES COMPANY SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $150,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against The Medicines Company -- MDCO
GlobeNewswire - Tue Feb 25, 9:00PM CST
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 22, 2014 to file lead plaintiff applications in a securities class action lawsuit against The Medicines Company (Nasdaq:MDCO), if they purchased the Company's securities during the period between February 20, 2013 and February 12, 2014, inclusive (the "Class Period"). This action is pending in the United States District Court for the District of New Jersey.
INVESTOR ALERT: Investigation of The Medicines Company Announced by Law Offices of Howard G. Smith
Business Wire - Tue Feb 25, 4:32PM CST
Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of The Medicines Company (NASDAQ:MDCO) concerning possible violations of federal securities laws. The investigation focuses on certain statements issued by The Medicines Company concerning its operations and financial prospects.
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in The Medicines Company to Contact Brower Piven Before the April 22, 2014 Lead Plaintiff Deadline -- MDCO
GlobeNewswire - Tue Feb 25, 3:05PM CST
Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of The Medicines Company ("Medicines" or the "Company") (Nasdaq:MDCO) securities during the period between February 20, 2013 and February 12, 2014, inclusive (the "Class Period").
After Cangrelor, The Medicines Company Gets Priority Review for New Drug
Eileen Rojas, The Motley Fool - Motley Fool - Tue Feb 25, 1:30PM CST
It at first you don't succeed, try again. The saying certainly describes The Medicines Company , as it regroups after the recent FDA advisory committee 2 to 7 vote against the approval of Cangrelor, used to prevent blood clots....
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in The Medicines Company to Contact Brower Piven Before the April 22, 2014 Lead Plaintiff Deadline (MDCO)
GlobeNewswire - Wed Mar 12, 12:14PM CDT
Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of The Medicines Company ("Medicines" or the "Company") (Nasdaq:MDCO) securities during the period between February 20, 2013 and February 12, 2014, inclusive (the "Class Period").
THE MEDICINES COMPANY SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Class Action Against THE MEDICINES COMPANY and Its Board of Directors and a Lead Plaintiff Deadline of April 22, 2014 -- MDCO
PR Newswire - Tue Mar 11, 1:33PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased The Medicines Company ("Medicines" or the "Company") (NasdaqGS: MDCO) securities between February 20, 2013 and February 12, 2014.
17.3% Return Seen to Date on SmarTrend Medicines Co Call (MDCO)
Comtex SmarTrend(R) - Fri Mar 07, 5:05PM CST
SmarTrend identified a Downtrend for Medicines Co (NASDAQ:MDCO) on January 29th, 2014 at $36.13. In approximately 1 month, Medicines Co has returned 17.33% as of today's recent price of $29.87.
Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in The Medicines Company of Class Action Lawsuit and Upcoming Deadline -- MDCO
GlobeNewswire - Fri Mar 07, 4:54PM CST
Pomerantz LLP has filed a class action lawsuit against The Medicines Company ("Medicines" or the "Company") (Nasdaq:MDCO) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 2:33-av-00001, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Medicines securities between February 20, 2013 and February 12, 2014 both dates inclusive (the "Class Period"). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.
The Medicines Company to Participate in 2014 Barclays Global Healthcare Conference
Marketwire - Thu Mar 06, 10:20AM CST
The Medicines Company (NASDAQ: MDCO) is scheduled to present at the 2014 Barclays Global Healthcare Conference in Miami, FL on March 12th at 1:00 PM Eastern Time.
EQUITY ALERT: The Rosen Law Firm, P.A. Announces the Filing of a Class Action Lawsuit Against The Medicines Company -- MDCO
GlobeNewswire - Tue Mar 04, 11:32AM CST
The Rosen Law Firm, P.A. announces that a class action lawsuit has been filed on behalf of purchasers of the securities of The Medicines Company (Nasdaq:MDCO) between February 20, 2013 and February 12. 2014, inclusive (the "Class Period") seeking remedies under the federal securities laws.
INVESTOR ALERT: Class Action Lawsuit Against The Medicines Company Announced by Law Offices of Howard G. Smith
Business Wire - Tue Mar 04, 9:32AM CST
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all purchasers of the securities of The Medicines Company (NASDAQ:MDCO) between February 20, 2013 and February 12, 2014, inclusive (the "Class Period").
EU Review for The Medicines Co.'s Oritavancin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 4:55PM CST
The Medicines Co.'s marketing authorization application for oritavancin accepted by the European Medicines Agency (EMA) for review.
Attention The Medicines Company Investors: The Medicines Company Misled Investors According to a Recently Filed Class Action
PR Newswire - Mon Mar 03, 2:19PM CST
Shareholder rights law firm Robbins Arroyo LLP announces that an investor of The Medicines Company (NASDAQ: MDCO) has filed a federal securities fraud class action complaint in the U.S. District Court for the District of New Jersey. The complaint alleges that the company and certain of its officers and directors violated the Securities and Exchange Act of 1934 between February 20, 2013 and February 12, 2014 (the "Class Period"). Medicines is a global pharmaceutical company that specializes in providing medical solutions for critical care patients in acute intensive care hospitals worldwide.
Medicines Co Has Returned 13.1% Since SmarTrend Recommendation (MDCO)
Comtex SmarTrend(R) - Fri Feb 28, 11:20AM CST
SmarTrend identified a Downtrend for Medicines Co (NASDAQ:MDCO) on January 29th, 2014 at $36.13. In approximately 1 month, Medicines Co has returned 13.12% as of today's recent price of $31.39.
The Medicines Company's MAA for oritavancin for acute bacterial skin and skin structure infections accepted for review by EMA
M2 - Fri Feb 28, 5:49AM CST
Hospital company The Medicines Company (NASDAQ:MDCO) stated on Thursday that its marketing authorisation application (MAA) for the investigational intravenous antibiotic oritavancin for the treatment of complicated skin and skin tissue infections (cSSTI) has been accepted for review by the European Medicines Agency (EMA).
INVESTOR ALERT: Class Action Lawsuit Against The Medicines Company Announced by Glancy Binkow & Goldberg LLP
Business Wire - Thu Feb 27, 9:32AM CST
Glancy Binkow & Goldberg LLP announces that a class action lawsuit has been filed on behalf of all purchasers of the securities of The Medicines Company (NASDAQ:MDCO) between February 20, 2013 and February 12, 2014, inclusive (the "Class Period"). If you purchased The Medicines Company shares during the Class Period, please contact us toll-free at (888) 773-9224, or at (212) 682-5340, or by email to shareholders@glancylaw.com to discuss this matter.
European Medicines Agency Accepts Marketing Authorization Application for The Medicines Company's Oritavancin
Marketwire Canada - Thu Feb 27, 7:45AM CST
The Medicines Company (NASDAQ: MDCO) today announced that the European Medicines Agency (EMA) has accepted for review a marketing authorization application (MAA) for the investigational intravenous antibiotic, oritavancin, for the treatment of complicated skin and skin tissue infections (cSSTI), caused by susceptible gram-positive bacteria, including by methicillin-resistant Staphylococcus aureus (MRSA), administered as a single dose.
Lifshitz & Miller Law Firm Announces Investigation of Emeritus Corporation, Nu Skin Enterprises, Inc., The Medicines Company, Thoratec Corporation and TriQuint Semiconductor, Inc.
PR Newswire - Wed Feb 26, 9:50AM CST
Emeritus Corporation
THE MEDICINES COMPANY SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $150,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against The Medicines Company -- MDCO
GlobeNewswire - Tue Feb 25, 9:00PM CST
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 22, 2014 to file lead plaintiff applications in a securities class action lawsuit against The Medicines Company (Nasdaq:MDCO), if they purchased the Company's securities during the period between February 20, 2013 and February 12, 2014, inclusive (the "Class Period"). This action is pending in the United States District Court for the District of New Jersey.
INVESTOR ALERT: Investigation of The Medicines Company Announced by Law Offices of Howard G. Smith
Business Wire - Tue Feb 25, 4:32PM CST
Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of The Medicines Company (NASDAQ:MDCO) concerning possible violations of federal securities laws. The investigation focuses on certain statements issued by The Medicines Company concerning its operations and financial prospects.
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in The Medicines Company to Contact Brower Piven Before the April 22, 2014 Lead Plaintiff Deadline -- MDCO
GlobeNewswire - Tue Feb 25, 3:05PM CST
Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of The Medicines Company ("Medicines" or the "Company") (Nasdaq:MDCO) securities during the period between February 20, 2013 and February 12, 2014, inclusive (the "Class Period").
After Cangrelor, The Medicines Company Gets Priority Review for New Drug
Eileen Rojas, The Motley Fool - Motley Fool - Tue Feb 25, 1:30PM CST
It at first you don't succeed, try again. The saying certainly describes The Medicines Company , as it regroups after the recent FDA advisory committee 2 to 7 vote against the approval of Cangrelor, used to prevent blood clots....
